New drug combo shows promise for Tough-to-Treat lymphoma

NCT ID NCT05249959

Recruiting now Disease control Sponsor: Fondazione Italiana Linfomi - ETS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether the drug loncastuximab tesirine, given after a short course of chemotherapy, can help people with mantle cell lymphoma whose cancer has returned or not responded to previous treatments, including BTK inhibitors. About 49 participants will receive the treatment, and researchers will measure how long the disease stays under control. The goal is to find a more effective option for this hard-to-treat cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: loncastuximab tesirine (ADCT-402) given after a short course of immunochemotherapy (rituximab, bendamustine, cytarabine)
What this could lead to: If successful, this could provide a new treatment option for patients with mantle cell lymphoma that has returned or not responded to prior therapies, potentially delaying disease progression.
What could go wrong: This is a small, early-phase (phase 2) study with only 49 participants, so results may not apply broadly. The drug combination may cause significant side effects, and it is not yet known if it improves survival compared to existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY MANTLE CELL LYMPHOMA RELAPSED MANTLE CELL LYMPHOMA

Contacts and locations

Locations

ASST Spedali Civili di Brescia
RECRUITING

Brescia, Italy, 25123, Italy
Dipartimento di Medicina Traslazionale e di Precisione - Policlinico Umberto I - Università "La Sapienza" Istituto Ematologia
RECRUITING

Roma, 00161, Italy
Divisione di Ematologia - A.O. Ospedali Riuniti Villa Sofia-Cervello
RECRUITING

Palermo, 90146, Italy
Divisione di Ematologia - IRCCS Policlinico S. Matteo di Pavia
RECRUITING

Pavia, 27100, Italy
Ematologia - Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova
RECRUITING

Reggio Emilia, 42123, Italy
Ematologia - Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
RECRUITING

Milan, 20133, Italy
Ematologia - Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l'Oncologia
RECRUITING

Genova, 16132, Italy
Ematologia - Ospedale delle Croci
RECRUITING

Ravenna, 48121, Italy
S.C di Ematologia - Ospedale Ca Foncello
RECRUITING

Treviso, 31100, Italy
S.C. Ematologia - A.S.O. "SS Antonio e Biagio e Cesare Arrigo"
RECRUITING

Alessandria, Italy
S.C. Ematologia - ASST Grande Ospedale Metropolitano Niguarda
RECRUITING

Milan, 20162, Italy
S.C. Ematologia Universitaria - A.O.U. Città della Salute e della Scienza di Torino
RECRUITING

Torino, 10126, Italy
S.C. di Ematologia - A.O. S. Croce e Carle
RECRUITING

Cuneo, 12100, Italy
SC Ematologia - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI)
RECRUITING

Trieste, 34121, Italy
SCDU Ematologia - AOU Maggiore della Carità di Novara
RECRUITING

Novara, 28100, Italy
U.O. Ematologia - AOU Integrata di Verona
RECRUITING

Verona, 37134, Italy
U.O. Ematologia - Istituto Clinico Humanitas
RECRUITING

Rozzano, 20089, Italy
U.O. di Ematologia - Ospedale degli Infermi di Rimini
RECRUITING

Rimini, 47923, Italy
U.O.C Ematologia e Trapianto - A.O. C. Panico
RECRUITING

Tricase, 73039, Italy
UOC Ematologia Oncologica - Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale
RECRUITING

Naples, 80131, Italy
Unità funzionale di Ematologia - Azienda Ospedaliera Universitaria Careggi
RECRUITING

Florence, 50141, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.